Resetting autoimmune disease with CAR cell therapies

Nature Medicine volume 32, pages 2007–2016 (2026)

Pathogenic B cell activation underlies many autoimmune diseases (AIDs), and their depletion is an attractive therapeutic approach. Chimeric antigen receptor (CAR)-expressing cells—initially developed and successfully used to treat certain cancers—are increasingly being developed to selectively deplete B cells and ‘reset’ the immune system in AIDs. In this Review, we survey this fast-developing field, providing insights on the current unmet needs in the treatment of AIDs and how CAR T cells could address these needs. In particular, we explore the concept of deep B cell depletion, discuss the currently available technologies and review the key targets (CD19 and B cell maturation antigen) relevant for the treatment of AIDs. We summarize current evidence on the efficacy, safety, risks and limitations of autologous and allogeneic CAR T cells in this setting. Finally, we discuss the future outlook—from a technological and clinical standpoint—for development of engineered CAR-expressing cell therapies for AIDs.

Related products

Catalog No.	Product Name	Description	Target
HX959011	Recombinant Human CD269/TNFRSF17 Protein	Recombinant Human CD269/TNFRSF17 Protein, C-Fc (HX959011) expressed in Mammalian Cells, spanning Met1-Ala54. Purity: >90% by SDS-PAGE. Highlights ●Fc Fusion — Enhanced stability with Protein A/G purification compatibility. ●Mammalian Expression — Proper folding and native glycosylation. ●High Purity — >90% purity verified by SDS-PAGE.

Recombinant Proteins

Antibodies

Assay Kits

Resetting autoimmune disease with CAR cell therapies

Quick access

Contact Us